ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2025
Decaffeinated coffee consumption and risk of total and site-specific cancer.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Association of coffee intake with risk of all-cause and colorectal cancer-specific mortality among individuals with colorectal cancer in the Multiethnic Cohort Study.Cancer causes & control : CCC · 2026Article
- Shared genetic architecture of psychoactive substance use and pan-cancer: insights from a large‑scale genome‑wide cross‑trait analysis.BMC medicine · 2026Article
- Regulatory Effects of Coffee/Chlorogenic Acid and Tea/Epigallocatechin-3-Current issues in molecular biology · 2025Review
- Application of Microbial Fermentation in Caffeine Degradation and Flavor Modulation of Coffee Beans.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCoffee is generally considered safe regarding cancer risk. However, concerns have emerged over methylene chloride, a chemical used in decaffeination, due to its carcinogenic properties. The potential cancer risk from methylene chloride residue in decaffeinated coffee remains unclear. PATIENTS AND
methodsThis prospective cohort study included 75 988 women (Nurses' Health Study, 1984-2020) and 45 349 men (Health Professionals Follow-up Study, 1986-2020). Decaffeinated coffee consumption was assessed at baseline and every 4 years using a validated food frequency questionnaire. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of total and 14 site-specific cancers associated with decaffeinated coffee consumption, adjusted for regular coffee intake and other potential confounding variables.
resultsDuring up to 36 years of follow-up, we documented 34 120 incident cancer cases (22 688 in women and 11 432 in men). Overall, decaffeinated coffee intake was not associated with higher total cancer risk [per 1 cup/day higher intake, HR 1.00 (95% CI 0.98-1.01)]. For specific cancer type, an inverse association was observed for colorectal [HR 0.96 (95% CI 0.92-0.99)] and aggressive prostate [HR 0.93 (95% CI 0.87-0.99)] cancer. An observed higher lung cancer risk for decaffeinated coffee attenuated to null when restricted to never smokers. However, we observed elevated bladder cancer risk among male never smokers: compared with nondrinkers, 0.1-0.9, 1-1.9, 2-2.9 and ≥3 cups/day of decaffeinated coffee intake were associated with HRs of 1.30 (95% CI 1.01-1.68), 1.42 (95% CI 1.00-2.03), 1.43 (95% CI 0.91-2.23), and 1.79 (95% CI 0.92-3.50), respectively, with borderline significant linear trends (P
conclusionsHigher decaffeinated coffee intake was not associated with total cancer risk. However, the observed significant higher risk of bladder cancer in men warrants further studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.